Importance of understanding injection device needs in rare disease patients

SMi reports: Deepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery. End Quote

(1888PressRelease) August 26, 2021 - Join us at the Oligonucleotide Therapeutics and Delivery conference in London and hear from leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest targeted therapy uniting the field’s biggest players to share their opinions.

Download a copy of your brochure to find out who will be speaking at the upcoming conference in September www.oligonucleotide.co.uk/1888pr7

Deep dive and spotlight sessions on:

MicroRNA Therapeutics: Targeting the Pathways of Human Disease
• MicroRNAs are short non-coding RNAs that regulate biochemical pathways by RNA interference (RNAi). Dysregulation of microRNAs is associated with many diseases.
• MicroRNA-21 has been implicated with fibrotic diseases and cancer
• The presentation shows the development of an anti-fibrotic antisense oligonucleotide (anti-miR-21) for the treatment of a genetic fibrotic kidney disease called Alport Syndrome, and summarizes the potential of anti-miR-21 as a drug to treat hepatocellular carcinoma
Ekkehard Leberer, Senior Consultant, ELBIOCON

Targeted cytoplasmic delivery of oligonucleotides
• Sapreme’s SPT001 compound improves cellular delivery of non-permeable biomolecules such as nucleic acids by up to 1000-fold by enhancing their escape from the endosome
• SPT001 conjugation to a targeting ligand can drive payload internalization and cytoplasmic delivery in a cell- or tissue specific manner – further improving the therapeutic window of any given antisense oligo or siRNA
• We will highlight recent proof-of-principle studies on nucleic acid delivery in vitro and in vivo
Guy Hermans, Chief Executive Officer, Sapreme Technologies B.V.

Register online: www.oligonucleotide.co.uk/1888pr7

Proudly Sponsored by ChemGenes | Genscript | Tosoh Bioscience

SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For more details and all delegate enquiries please contact Alia Malick on: +44 (0)20 7827 6168.
For media queries please contact Jinna Sidhu at hsidhu ( @ ) smi-online dot co dot uk or call +44 (0)20 7827 6088 dot

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

###

space

Other Related Press Releases